JP2022554019A5 - - Google Patents
Info
- Publication number
- JP2022554019A5 JP2022554019A5 JP2022525889A JP2022525889A JP2022554019A5 JP 2022554019 A5 JP2022554019 A5 JP 2022554019A5 JP 2022525889 A JP2022525889 A JP 2022525889A JP 2022525889 A JP2022525889 A JP 2022525889A JP 2022554019 A5 JP2022554019 A5 JP 2022554019A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- free base
- disease
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932652P | 2019-11-08 | 2019-11-08 | |
| US62/932,652 | 2019-11-08 | ||
| PCT/US2020/059287 WO2021092292A1 (en) | 2019-11-08 | 2020-11-06 | FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554019A JP2022554019A (ja) | 2022-12-27 |
| JP2022554019A5 true JP2022554019A5 (cg-RX-API-DMAC7.html) | 2023-11-09 |
Family
ID=75846182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525889A Withdrawn JP2022554019A (ja) | 2019-11-08 | 2020-11-06 | 補体成分C5a受容体の遊離塩基結晶形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11026935B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4054577A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022554019A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220098179A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114641289A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020378061A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022007488A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3155596A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022001173A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292317A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005403A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021092292A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202305622B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020380367B2 (en) | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| CA3192880A1 (en) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| US20260027049A1 (en) | 2024-07-23 | 2026-01-29 | Amgen Inc. | Avacopan formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031548B (zh) * | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
| JP5819730B2 (ja) * | 2008-12-22 | 2015-11-24 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| JP6898229B6 (ja) * | 2014-09-29 | 2021-07-28 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト製造における方法及び中間体 |
| AU2020380367B2 (en) * | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
-
2020
- 2020-11-06 AU AU2020378061A patent/AU2020378061A1/en not_active Abandoned
- 2020-11-06 BR BR112022007488A patent/BR112022007488A2/pt not_active IP Right Cessation
- 2020-11-06 KR KR1020227018961A patent/KR20220098179A/ko not_active Withdrawn
- 2020-11-06 IL IL292317A patent/IL292317A/en unknown
- 2020-11-06 CA CA3155596A patent/CA3155596A1/en active Pending
- 2020-11-06 US US17/091,019 patent/US11026935B2/en active Active
- 2020-11-06 JP JP2022525889A patent/JP2022554019A/ja not_active Withdrawn
- 2020-11-06 CN CN202080077446.8A patent/CN114641289A/zh active Pending
- 2020-11-06 MX MX2022005403A patent/MX2022005403A/es unknown
- 2020-11-06 EP EP20884944.8A patent/EP4054577A4/en not_active Withdrawn
- 2020-11-06 WO PCT/US2020/059287 patent/WO2021092292A1/en not_active Ceased
-
2021
- 2021-05-04 US US17/307,865 patent/US20220096453A1/en not_active Abandoned
-
2022
- 2022-05-04 CL CL2022001173A patent/CL2022001173A1/es unknown
-
2023
- 2023-04-24 US US18/305,611 patent/US20230381167A1/en not_active Abandoned
- 2023-05-25 ZA ZA2023/05622A patent/ZA202305622B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501789A5 (cg-RX-API-DMAC7.html) | ||
| TWI344957B (en) | Chemical process and intermediates | |
| US12534495B2 (en) | Compositions and methods for treating CNS disorders | |
| JP2000500154A (ja) | モルホリン誘導体及び治療薬としてのそれらの使用 | |
| JP2851480B2 (ja) | 結晶オキサチオラン誘導体 | |
| JP2023116503A5 (cg-RX-API-DMAC7.html) | ||
| JP2023120208A5 (cg-RX-API-DMAC7.html) | ||
| JP2021181446A5 (cg-RX-API-DMAC7.html) | ||
| JP2023519891A5 (cg-RX-API-DMAC7.html) | ||
| EA011164B1 (ru) | Производные пиримидина для профилактики вич-инфекции | |
| JP2021063129A5 (cg-RX-API-DMAC7.html) | ||
| US20210308149A1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| JP2008508885A5 (cg-RX-API-DMAC7.html) | ||
| JP2001507023A (ja) | トリアゾロ[4,5−d]ピリミジニル誘導体および医薬としてのその使用 | |
| JP2023139178A (ja) | 癌の組合せ治療 | |
| TW202430149A (zh) | N,n-二甲基色胺之結晶形式及其使用方法 | |
| JP2010534669A5 (cg-RX-API-DMAC7.html) | ||
| US20130345418A1 (en) | Process for purification of aprepitant | |
| TWI399375B (zh) | 嗎啉化合物之鹽 | |
| Edrees | Relapsing polychondritis: a description of a case and review article | |
| CN102131803A (zh) | (1r,2s,3r)-1-(2-(异噁唑-3-基)-1h-咪唑-4-基)丁烷-1,2,3,4-四醇的固体形式及其使用方法 | |
| JP2024520897A5 (cg-RX-API-DMAC7.html) | ||
| PT1896439E (pt) | Base cristalina de escitalopram e comprimidos orodispersíveis compreendendo base de escitalopram | |
| RU2012136921A (ru) | Твердые формы, содержащие производные циклопропиламида | |
| JP2022502516A5 (cg-RX-API-DMAC7.html) |